These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 2557715)
1. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer]. Bartel U; Johannsen B; Reiss H; Elling D Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715 [TBL] [Abstract][Full Text] [Related]
2. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144 [TBL] [Abstract][Full Text] [Related]
3. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study. Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729 [TBL] [Abstract][Full Text] [Related]
4. [Is follow-up of breast cancer with CEA and CA 15-3 justified?]. Fritsche E; Benz J Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832 [TBL] [Abstract][Full Text] [Related]
5. [MCA and CA 15-3 in the follow-up of patients with breast cancer]. Hammer J; Track C; Hohenwallner W; Seewald DH; Zoidl JP; Wimmer E Strahlenther Onkol; 1992 Feb; 168(2):102-6. PubMed ID: 1542844 [TBL] [Abstract][Full Text] [Related]
6. [The value of CA 125 determination in the serum of patients with ovarian cancer]. Bartel U; Johannsen B; Elling D Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673 [TBL] [Abstract][Full Text] [Related]
7. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer]. Engel K; Schmid H; Hanke J; Kaufmann M; Müller A Geburtshilfe Frauenheilkd; 1988 May; 48(5):309-12. PubMed ID: 3165077 [TBL] [Abstract][Full Text] [Related]
8. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases]. Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740 [TBL] [Abstract][Full Text] [Related]
9. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation. Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728 [TBL] [Abstract][Full Text] [Related]
10. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644 [TBL] [Abstract][Full Text] [Related]
11. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243 [TBL] [Abstract][Full Text] [Related]
12. MCA performance in preoperative breast cancer patients. Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer. Eskelinen M; Tikanoja S; Brown J Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995 [TBL] [Abstract][Full Text] [Related]
14. [CA 15.3 and early diagnosis of recurrence in breast cancer]. Basuyau JP; Brunelle P; Charrot P; Chevallier B; Delapierre F; Graic Y; Julien JP; Veyret C Bull Cancer; 1993 Mar; 80(3):213-8. PubMed ID: 8173173 [TBL] [Abstract][Full Text] [Related]
15. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer]. Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042 [TBL] [Abstract][Full Text] [Related]
16. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K]. Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444 [TBL] [Abstract][Full Text] [Related]
17. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients. Einarsson R; Lindman H; Bergh J Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674 [TBL] [Abstract][Full Text] [Related]
18. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106 [TBL] [Abstract][Full Text] [Related]
19. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA. Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204 [TBL] [Abstract][Full Text] [Related]
20. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results. Zervoudis S; Peitsidis P; Iatrakis G; Panourgias E; Koureas A; Navrozoglou I; Dubois JB J BUON; 2007; 12(4):487-92. PubMed ID: 18067207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]